奥赛康：股东中亿伟业拟减持不超过约1856万股

Group 1 - The core revenue composition of Aosaikang for the year 2024 is 97.92% from the pharmaceutical manufacturing industry and 2.08% from other businesses [1] Group 2 - Aosaikang announced on August 15 that its shareholder, Zhongyi Weiye Holdings Co., Ltd., holds approximately 120 million shares, accounting for about 12.95% of the total share capital [3] - Zhongyi Weiye plans to reduce its holdings by up to approximately 18.56 million shares, not exceeding 2% of the total share capital, within three months after the announcement date [3]